Moreover, patients with the NPM1 mutation and adverse-risk cytogenetic abnormalities, even in the absence of FLT3-ITD mutation, are categorized as adverse-risk patients [31], indicating the inadequate tumor suppressor potential of the NPM1 mutation and the predominance of cytogenetic risk over molecular risk [14]. Here, NPM1 is linked to neoplasm.